Johann De Bono

Title: Johann De Bono: Innovator in Cancer Treatment

Introduction

Johann De Bono is a prominent inventor based in London, GB, known for his significant contributions to cancer treatment. With a total of 2 patents, he has focused on developing innovative methods to combat prostate cancer, particularly in cases resistant to traditional therapies.

Latest Patents

De Bono's latest patents include groundbreaking methods for treating androgen deprivation therapy-resistant prostate cancer. His invention provides a method of treatment that involves administering a therapeutically effective amount of an inhibitor of IL-23 and/or IL-23R to patients in need. This method is particularly relevant for those suffering from castration-resistant prostate cancer (CRPC). Additionally, he has developed a method for predicting the development of resistance to androgen deprivation therapy in prostate cancer patients. Another notable patent describes methods and compositions for treating cancer, which involve administering a 17α-hydroxylase/C-lyase inhibitor, such as abiraterone acetate, in combination with other therapeutic agents.

Career Highlights

Throughout his career, Johann De Bono has worked with esteemed organizations, including the Fondazione per l'Istituto Oncologico di Ricerca and The Institute of Cancer Research: Royal Cancer Hospital. His work has significantly advanced the understanding and treatment of cancer, particularly prostate cancer.

Collaborations

De Bono has collaborated with notable colleagues in the field, including Andrea Alimonti and Arianna Calcinotto. These partnerships have contributed to the development of innovative cancer therapies and have furthered research in oncology.

Conclusion

Johann De Bono's contributions to cancer treatment through his patents and collaborations highlight his role as a leading inventor in the field. His innovative approaches continue to pave the way for advancements in the treatment of prostate cancer.